The Bridge Program is a consortium of 15 companies, universities and industry associations aiming to transfer practical skills on pharmaceutical commercialisation through training and direct exposure to industry practitioners.
The Bridge Program aims to address a key barrier in Australia's life sciences sector - lack of commercialisation skills and business acumen across researchers and life science entrepreneurs. Across the innovation ecosystem, start-up businesses struggle to identify and employ managerial talent who possess the necessary business development skills.
Launching in June 2017, the program will select 100 participants annually from across Australia each year for two years. They will take part in face-to-face and online training in the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that contribute to research translation and the commercialisation of medicines, including a three-day residential study course aligning with the AusBiotech conference. In addition to this, regional information and networking events will be organised for the participants with top pharmaceutical companies operating globally.
Visit The Bridge Program website to learn more.
|Consortium Members||Abbvie, Amgen, Australian Private Equity & Venture Capital Association Limited, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, CSL Limited, Janssen-Cilag, Macquarie University, Medical Research Commercialisation Fund, Medicines Australia, MSD Australia, Mundipharma, Novartis, Queensland University of Technology|
|Project duration||March 2017 - February 2019|
|Contact||Kate Regnault, Project Officer, The Bridge Program - email@example.com|